Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling

dc.contributor.author
Berenjeno, Inma M.
dc.contributor.author
Piñeiro, Roberto
dc.contributor.author
Castillo, Sandra D.
dc.contributor.author
Pearce, Wayne
dc.contributor.author
McGranahan, Nicholas
dc.contributor.author
Dewhurst, Sally M.
dc.contributor.author
Meniel, Valerie
dc.contributor.author
Birkbak, Nicolai J.
dc.contributor.author
Lau, Evelyn
dc.contributor.author
Sansregret, Laurent
dc.contributor.author
Morelli, Daniele
dc.contributor.author
Kanu, Nnennaya
dc.contributor.author
Srinivas, Shankar
dc.contributor.author
Graupera i Garcia-Milà, Mariona
dc.contributor.author
Parker, Victoria E. R.
dc.contributor.author
Montgomery, Karen G.
dc.contributor.author
Moniz, Larissa S.
dc.contributor.author
Scudamore, Cheryl L.
dc.contributor.author
Phillips, Wayne A.
dc.contributor.author
Semple, Robert K.
dc.contributor.author
Clarke, Alan
dc.contributor.author
Swanton, Charles
dc.contributor.author
Vanhaesebroeck, Bart
dc.date.issued
2018-07-27T12:26:47Z
dc.date.issued
2018-07-27T12:26:47Z
dc.date.issued
2017-11-24
dc.date.issued
2018-07-24T11:55:27Z
dc.identifier
https://hdl.handle.net/2445/124039
dc.identifier
29170395
dc.description.abstract
Mutations in PIK3CA are very frequent in cancer and lead to sustained PI3K pathway activation. The impact of acute expression of mutant PIK3CA during early stages of malignancy is unknown. Using a mouse model to activate the Pik3ca(H1047R) hotspot mutation in the heterozygous state from its endogenous locus, we here report that mutant Pik3ca induces centrosome amplification in cultured cells (through a pathway involving AKT, ROCK and CDK2/Cyclin E-nucleophosmin) and in mouse tissues, and increased in vitro cellular tolerance to spontaneous genome doubling. We also present evidence that the majority of PIK3CA(H1047R) mutations in the TCGA breast cancer cohort precede genome doubling. These previously unappreciated roles of PIK3CA mutation show that PI3K signalling can contribute to the generation of irreversible genomic changes in cancer. While this can limit the impact of PI3K-targeted therapies, these findings also open the opportunity for therapeutic approaches aimed at limiting tumour heterogeneity and evolution.
dc.format
15 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Nature Publishing Group
dc.relation
Reproducció del document publicat a: http://dx.doi.org/10.1038/s41467-017-02002-4
dc.relation
Nature Communications, 2017, num. 8
dc.relation
http://dx.doi.org/10.1038/s41467-017-02002-4
dc.relation
info:eu-repo/grantAgreement/EC/FP7/317250/EU//VESSEL
dc.rights
cc by (c) Berenjeno et al., 2017
dc.rights
http://creativecommons.org/licenses/by/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject
Càncer
dc.subject
Oncogènesi
dc.subject
Cancer
dc.subject
Carcinogenesis
dc.title
Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)